Cologuard(R) Growth Trajectory Increases to 34,000 Completed Tests, Generates $12.6M in Revenue in Third Quarter 2015


MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq:EXAS) today announced that the company continued its strong performance during the third quarter ended Sept. 30, 2015, completing 34,000 Cologuard tests, an increase of 60 percent from the second quarter, which resulted in $12.6 million in revenues. The cumulative number of ordering physicians grew to 21,000 during the quarter, an increase of 42 percent.

Read More

Topics: Investor Relations

Exact Sciences Highlights CMS Advisory Panel's Unanimous Vote to Maintain Medicare Reimbursement Rate for Cologuard®

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) Advisory Panel on Clinical Diagnostic Laboratory Tests voted unanimously to maintain Medicare's current crosswalk pricing ($492.72) for Cologuard. The 11-0 vote, including one abstention, came after the Clinical Lab Fee Schedule's July 16, 2015 public meeting. Exact Sciences' Chairman and CEO Kevin Conroy presented a proposal at the July 16th meeting to crosswalk Cologuard from its current G-code to a CPT code. Following today's vote, Conroy issued this statement:

Read More

Topics: Exact Sciences News